


# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

## PCT

To:

GOLDIN Douglas M.  
J.A. KEMP & CO.  
14 South Square  
Gray's Inn  
London WC1R 5LX  
GRANDE BRETAGNE



NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year)

23.08.2000

Applicant's or agent's file reference  
01528.001

178368

**IMPORTANT NOTIFICATION**

International application No.  
PCT/US99/11977

International filing date (day/month/year)  
28/05/1999

Priority date (day/month/year)  
29/05/1998

Applicant  
CHIRON CORPORATION et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Digiusto, M

Tel. +49 89 2399-8162



# PATENT COOPERATION TREATY

## PCT

REC'D 25 AUG 2000

WIPO

PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 01528.001	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/11977	International filing date (day/month/year) 28/05/1999	Priority date (day/month/year) 29/05/1998
International Patent Classification (IPC) or national classification and IPC A61K39/095		
Applicant CHIRON CORPORATION et al.		

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 7 sheets, including this cover sheet.
  - ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

- This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/12/1999	Date of completion of this report 23.08.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Bradbrook, D Telephone No. +49 89 2399 7413 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/11977

## I. Basis of this report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

### Description, pages:

1-10 as originally filed

### Claims, No.:

1-16 as originally filed

### Drawings, sheets:

1/3-3/3 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 8-14, 16 for 1A.

because:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/11977

- ☒ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

- ☐ no international search report has been established for the said claims Nos. .

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	4,11
	No:	Claims	1-3,5-10,12-16
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-16
Industrial applicability (IA)	Yes:	Claims	1-7,15
	No:	Claims	

### 2. Citations and explanations

**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/11977

---

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

Section III

1. Non establishment of opinion

Claims 8-14 and 16 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Section V

2. Reference is made to the following documents:

- D1: WO-A-90 06696 (Praxis Biologics Inc. and Rijksinstituut v. Volksgez.; 28.06.90);
- D2: Liebermann et al., JAMA, Vol.275, pp.1499-1503 (1996);
- D3: Product information from S.C.S. Farmacia Manes, Argentina;
- D4: Debbag et al., Clin.Infect.Dis., Vol.21, p.790, Abstr.A420 (1995);
- D5: Granhoff et al., Infection and Immunity, Vol.65, pp.1710-1715 (1997).

D1 discloses vaccine formulations comprising outer-membrane vesicles, Class 1 outer membrane proteins (OMPs), or epitope-containing fragments or oligopeptides thereof, from *Neisseria meningitidis*. Effective vaccines should comprise OMPs from *N. meningitidis* group B, and may additionally contain meningococci A and C polysaccharides, preferably coupled to a protein or polypeptide carrier such as a nontoxic mutant bacterial toxin (CRM); CRM197 is cited as the carrier protein in claim 41. The vaccine may also contain an adsorbant such as alum. See "Detailed description", p.7-p.10, para.1.

D2 concerns a vaccine comprising *N. meningitidis* groups A and C oligosaccharide-protein conjugates (see abstract).

D3 gives information on the VA-MENGOC-BC vaccine, which comprises polysaccharides from *N. meningitidis* group C conjugated to outer membrane proteins from group B (see "Composición").

D4 concerns an evaluation of adverse reactions to the VA MENGOC-BC vaccine, and is cited to show that said vaccine was in use before the priority date of the present application.

D5 discloses enhanced antibody responses when using MF59 adjuvant with *N. meningitidis* and *Haemophilus influenzae* conjugate vaccines (abstract).

**3. Novelty (Article 33(2) PCT)**

- a. D1 seems to anticipate the subject-matter of independent claims 1, 8, 15 and 16, as well as dependent claims 2, 3, 5-7, 9, 10 and 12-14. Therefore, these claims are not considered to be novel over D1.
- b. Inasmuch as claim 1 does not exclude an embodiment wherein the NmB outer membrane protein is the first carrier to which the NmC oligosaccharide is conjugated, this composition is not distinguishable from that with the VA-MENGOC-BC vaccine, described in D3. Therefore, claims 1-3, 6-10, and 13-16 appear not to be novel over D3.
- c. In claims 4 and 11, the carrier protein is defined as CRM 197. Although this same carrier protein is also used in D1, the context of its use is very specific (see claim 41) and is not considered to apply necessarily to the compositions disclosed therein in a general manner. Thus, claims 4 and 11 would appear to be novel.

**4. Inventive step (Article 33(3) PCT)**

- a. Claims 4 and 11 are not considered to be inventive: in D1, CRMs as a group are proposed as carrier proteins, and CRM197 in particular is preferred in one particular embodiment (claim 41). The skilled person would readily understand that CRM197 is generally applicable as a carrier protein for the vaccines in D1 and would require no inventive skill in using it as such. Moreover, polysaccharides from *N. meningitidis* groups A and C were coupled to the carrier CRM197 in a vaccine in D2 (p.1500, col.2: "Vaccines"). Thus, said claims do not appear to be inventive over D1 alone, or in combination with D2.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/11977

- b. It is noted that the advantageous use of adjuvant MF59 with meningococcal vaccines is disclosed in D5.

5. Industrial applicability (Article 33(4) PCT)

For the assessment of the present claims 8-14 and 16 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Section VII

6. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1-D3 and D5 is not mentioned in the description, nor are these documents identified therein.

Section VIII

7. The following objections arise under Article 6 PCT:
- a. Abbreviations in the claims, such as NmB and NmC, should have been written out in full, at least in the independent claims (PCT Guidelines C-III 4.2).
  - b. Claim 5 should have read "The immunogenic composition of claim 1 **wherein** ...".
  - c. The vague and imprecise statement in the description, p.6, I.3-4, referring to the "spirit" of the invention, implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity when used to interpret them (see also PCT Guidelines, C-III, 4.3a).



## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 27 January 2000 (27.01.00)	
International application No. PCT/US99/11977	Applicant's or agent's file reference 01528.001
International filing date (day/month/year) 28 May 1999 (28.05.99)	Priority date (day/month/year) 29 May 1998 (29.05.98)
Applicant GRANOFF, Dan, M. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

20 December 1999 (20.12.99)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Diana Nissen Telephone No.: (41-22) 338.83.38
---	--

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>01528.001</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 11977</b>	International filing date (day/month/year) <b>28/05/1999</b>	(Earliest) Priority Date (day/month/year) <b>29/05/1998</b>
Applicant <b>CHIRON CORPORATION et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/11977

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-14 16  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 8-14,16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Claims Nos.: 8-14 16

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 39/095, 39/39, 9/127, 39/385</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/61053</b>
			<b>(43) International Publication Date:</b> 2 December 1999 (02.12.99)
<b>(21) International Application Number:</b> PCT/US99/11977 <b>(22) International Filing Date:</b> 28 May 1999 (28.05.99)  <b>(30) Priority Data:</b> 60/087,351 29 May 1998 (29.05.98) US 60/106,446 30 October 1998 (30.10.98) US  <b>(71) Applicant (for all designated States except US):</b> CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GRANOFF, Dan, M. [US/US]; 10 Creston Road, Berkeley, CA 94708 (US). AABERGE, Ingeborg, S. [NO/NO]; Statens Institutt for Folkehelse, P.O. Box 4404, N-0403 Oslo (NO). HANEBERG, Bjorn [NO/NO]; Statens Institutt for Folkehelse, P.O. Box 4404, N-0403 Oslo (NO). HOLST, Johan [NO/NO]; Statens Institutt for Folkehelse, P.O. Box 4404, N-0403 Oslo (NO). RAFF, Howard [US/US]; 296 Greene Street, Mill Valley, CA 94941 (US).  <b>(74) Agent:</b> HARBIN, Alisa, A.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), O patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> COMBINATION MENINGITIDIS B/C VACCINES			
<b>(57) Abstract</b>  The present invention is directed to a combination vaccine for <i>Neisseria meningitidis</i> comprising outer membrane proteins from serogroup B and oligosaccharides from serogroup C, and its use for the prevention or treatment of disease.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## COMBINATION MENINGITIDIS B/C VACCINES

### CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to U.S. provisional application Serial  
5 Numbers 60/087,351 filed May 29, 1998 and 60/106,446 filed October 30, 1998, each of which is incorporated herein by reference in its entirety.

### FIELD OF THE INVENTION

The present invention relates to combination immunogenic compositions and  
10 vaccines for *Neisseria meningitidis* B and C and to methods of inducing an immune response by administering the same.

### BACKGROUND OF THE INVENTION

Serogroup B and C strains of *Neisseria meningitidis* (Nm) together account  
15 for the majority of invasive diseases in Europe and the United States. Vaccines against individual Nm serogroups are presently available. The NIPH (National Institute of Public Health of Norway) NmB vaccine is safe, elicits strain-specific immunity in children and adults, and is efficacious in preventing NmB disease in adolescents. This vaccine has been typically combined with meningococcal C polysaccharide vaccine and given with alum. The  
20 plain polysaccharide vaccine component, however, is not effective in infants and young children. The Chiron NmC conjugate (conj.) vaccine is also safe, elicits high titers of serum bactericidal antibody in infants vaccinated as young as two and three months of age, and

- 2 -

induces immunologic B cell memory to the unconjugated NmC polysaccharide. Since both serogroups cause disease, a combination vaccine which induces an immune response to both serogroups would be highly advantageous.

## SUMMARY OF THE INVENTION

5 In one aspect, the present invention relates to an immunogenic composition or vaccine comprising NmC oligosaccharides conjugated to a carrier protein, NmB outer membrane proteins, and a carrier. In a preferred embodiment, the carrier protein is CRM<sub>197</sub>, a non-toxic diphtheria toxin, the NmB outer membrane proteins are presented as proteoliposomic vesicles, and the carrier is aluminum hydroxide or MF59.

10 In another aspect, the present invention relates to a method of inducing an immune response to NmB and NmC, or vaccinating, comprising the administration of an immunologically effective amount of an immunogenic composition comprising NmC oligosaccharides conjugated to a carrier protein, NmB outer membrane proteins, and a carrier.

## 15 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B summarize NmB IgG and NmC IgG antibody titers, respectively, as determined by ELISA.

Figures 2A and 2B summarize of titers of serum bactericidal antibody to NmB and NmC, respectively.

20 Figure 3 summarizes the comparison of antibody ratios to NmB and NmC induced by the combination vaccine in MF59 adjuvant vs. Alum.

Figure 4 summarizes the comparison of antibody ratios to NmB and NmC induced by the combination vaccine vs. the respective monovalent vaccine.

## 25 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

A combination vaccine for NmB and NmC which induces an immune response to both serogroups that is not significantly different from the immune response induced by each serogroup alone is described. The immunogenicity of the NIPH NmB vaccine (referred to herein as "NmB" or "MenB" vaccines) and the Chiron NmC conjugate vaccine (referred to herein as "NmC conj." or "MenC conj."), alone, in combination, and in combination with

30



the adjuvant MF59 is described herein.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of immunology and microbiology. Such techniques are explained fully in the literature. See, e.g., *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.) and *Handbook of Experimental Immunology*, Vols. I-IV (D.M. Weir and C.C. Blackwell eds., Blackwell Scientific Publications).

As used herein, the term "immunogenic" refers to material which induces the production of antibody upon administration to a vertebrate, including humans.

As used herein, the term "carrier" refers to a pharmaceutically acceptable component other than the NmB or NmC immunogenic component. The carrier can be organic, inorganic, or both. Suitable carriers well known to those of skill in the art and include, without limitation, large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes) and inactive virus particles. The carrier can also function as an immunostimulatory agent, e.g., adjuvant. Suitable adjuvants are well known to those of skill in the art.

As used herein, the term "immunologically effective amount," means the administration of that amount, either in a single dose or as part of a series, that is effective for inducing the production of antibody for either the treatment or prevention of disease. This amount will vary depending upon a variety of factors, including the physical condition of the subject, and can be readily determined by someone of skill in the art.

As used herein, the term "vaccine" means an immunogenic composition which is able to induce a microbicidal immune response. Preferably, the vaccines of the present invention elicit a bactericidal antibody response.

The present invention is directed, in part, to immunogenic compositions which induce an immune response to both Meningitidis B and C. In preferred embodiments of the invention, the immunogenic composition comprises NmB outer membrane protein, and NmC oligosaccharide conjugated to a first carrier.

The NmB protein preferably comprises partially purified outer membrane proteins from strain 44/76 (B15:P1.7, 16:L3,7,9). The partially purified outer membrane proteins are preferably present as proteoliposomic vesicles as a result of the extraction process

using deoxycholate. The dosage of NmB is expressed in  $\mu\text{g}$  of protein. Preferably, the NmB immune composition/vaccine components can be obtained from the National Institute of Public Health of Norway (NIPH). The NmB/alum vaccine comprises 0.05 mg/ml NmB protein, 3.33 mg/ml  $\text{Al}(\text{OH})_3$  (alum), and 0.10 mg/ml thiomersalsodium.

The Chiron oligosaccharide represents NmC polysaccharide fragments of from  
5 preferably about 12 to about 22 repeating units. Preferably, the NmC oligosaccharide is conjugated to a first carrier. The dosage of NmC conjugate or polysaccharide is expressed in  $\mu\text{g}$  of sialic acid. An NmC vaccine containing unconjugated polysaccharide (referred to herein as "NmC polysaccharide" or "MenC Ps") can also be used. MenC Ps is a crude isolate comprising polysaccharides preferably from about 60 to about 80 repeating units.

10 In preferred embodiments of the invention, the first carrier is a protein, polysaccharide, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid copolymer, lipid aggregate, or inactive virus particle. More preferably, the first carrier is a protein. Most preferably, the first carrier is CRM<sub>197</sub>. Ten  $\mu\text{g}$  of oligosaccharide to 12.5-33  $\mu\text{g}$  CRM<sub>197</sub> (i.e., to maintain a oligo/protein ratio of from about 0.3 to about 0.8) is preferably  
15 used per dose. More preferably, about 20  $\mu\text{g}$  of CRM<sub>197</sub> can be used.

In preferred embodiments of the invention, the immunogenic composition comprises a second carrier, preferably, aluminum hydroxide (alum) or MF59. Alum can be obtained from Superfos, Bedbaek, Denmark, and is a 3% solution. When present, about 1 mg to about 1.67 mg of alum is used per dose. MF59 is a micro-fluidized emulsion of squalene  
20 in water that has been shown to be safe and to augment serum antibody responses to a variety of investigational vaccines. MF59 comprises about 5% squalene, 0.5% Tween 80 and about 0.5% Span 85. The adjuvant MF59 is described in PCT publication No. WO 90/14837, incorporated herein by reference in its entirety. MF59 can be made according to the procedures described in, for example, Ott *et al.*, *Vaccine Design: The Subunit And Adjuvant*  
25 *Approach*, 1995, M.F. Powell and M.J. Newman, Eds., Plenum Press, New York, p. 277-296; Singh *et al.*, *Vaccine*, 1998, 16, 1822-1827; Ott *et al.*, *Vaccine*, 1995, 13, 1557-1562; and Valensi *et al.*, *J. Immunol.*, 1994, 153, 4029-39, the disclosures of which are incorporated herein by reference in their entirety.

The immunogenic composition of the invention will employ an  
30 immunologically effective amount of the antigens. That is, there will be included an amount

- 5 -

of antigen which, in combination with the adjuvant, will cause the subject to produce a specific and sufficient immunological response, preferably a T or B lymphocyte response, so as to impart protection to the subject from the subsequent exposure to *Neisseria*.

No single dose designation can be assigned which will provide specific guidance for each and every antigen which can be employed in this invention. The effective  
5 amount of antigen will be a function of its inherent activity and purity and is empirically determined by those of ordinary skill in the art via routine experimentation.

The immunogenic compositions according to the present invention comprise an immunostimulatory amount of *Neisseria* antigen. An immunostimulatory amount is that amount which is sufficient to induce a measurable humoral or cellular immune response. For  
10 example, the immunogenic compositions of the present invention comprise about 1 nanogram to about 1000 micrograms of antigen or about 10 nanograms to about 800 micrograms of antigen. In some preferred embodiments, the immunogenic compositions contain about 0.1 to about 500 micrograms of antigen. In some preferred embodiments, the immunogenic compositions contain about 1 to about 350 micrograms of antigen. In some preferred  
15 embodiments, the immunogenic compositions contain about 25 to about 250 micrograms of antigen. In some preferred embodiments, the immunogenic compositions contain about 100 micrograms of antigen. One skilled in the art can readily formulate an immunogenic composition comprising any desired amount of antigen, which can be empirically determined by those of ordinary skill in the art via routine experimentation. The immunogenic  
20 compositions can be conveniently administered in unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980), the disclosure of which is incorporated herein by reference in its entirety.

The present invention is also directed to vaccines comprising any of the  
25 immunogenic compositions described above.

The present invention is also directed to methods of inducing an immunologic response to NmB and NmC comprising administering an immunologically effective amount of an immunogenic composition described above to a human. Administration can be by any mode known to those skilled in the art including by oral, parenteral, pulmonary, transdermal,  
30 rectal, intraperitoneal, intramuscular, or subcutaneous routes.

The invention is further illustrated by way of the following examples which are intended to elucidate the invention. The foregoing examples are meant to illustrate the invention and are not to be construed to limit the invention in any way. Those skilled in the art will recognize modifications that are within the spirit and scope of the invention. All references cited herein are hereby incorporated by reference in their entirety.

5

## EXAMPLES

### Example 1: ELISA results

Groups of guinea pigs (n=15 animals) were assigned to receive one of the following vaccines set forth in Table 1:

10

**Table 1**

<u>Group</u>	<u>Components</u>	<u>Amount per dose</u>
Group 1	NmC conj./alum	10 µg /1 mg
Group 2	NmB/alum	25 µg/1 mg
Group 3	NmC polysaccharide/NmB/alum	10 µg /25 µg /1 mg
15 Group 4	NmC conj./NmB/alum	10 µg/25 µg/1 mg
Group 5	NmC conj./NmB/MF59	10 µg /25 µg /0.5 ml.

Group 6 (n=5) comprised control animals that received alum alone.

Eighty guinea pigs were randomized into the groups set forth above and received one of six vaccine combinations. For the data presented in Table 2, each animal received two injections, IM, separated by 28 days. Serum samples were obtained prior to each injection, and 18 days after the second injection. For the data presented in Figures 1A and 1B, each animal received two immunizations separated by six weeks. Each dose consisted of two 0.25 ml IM injections. Serum samples were obtained immediately prior to each injection, and 14 or 18 days after the second injection.

25

Serum samples were assayed for IgG anticapsular antibody concentrations to NmC (Table 2 and Figure 1A) and for IgG anti-outer membrane vesicle antibody concentrations to NmB by ELISA (Figure 1B). The ELISA data were generated in a representative assay of individual animal sera (Table 2) and also expressed as averages from a plurality of assays (Figures 1A and 1B). The summary ELISA data set forth in Table 2 are, therefore, expressed as geometric means.

30

- 7 -

For the ELISA, MCPS-ADH (NmC polysaccharide-adipic acid dihydrazide) conjugate or outer membrane vesicle (OMV) components was coated onto polystyrene microtiter plates overnight at 4°C, 1 µg/ml, 100 µl/well. On each coated plate, 100 µl/well of each of a reference standard (i.e., pooled guinea pig serum), a positive control, a negative control, and the serum samples were two-fold serially diluted in a buffer containing 75 µM ammonium thiocyanate, and incubated for two hours at room temperature. Rabbit anti-guinea pig IgG antibody conjugated to peroxidase was added to the wells (100 µl/well). After 2 hours, the colorimetric substrate 3,3',5,5', Tetramethylbenzidine (TMB) (100 µl/well) was added, and the color was developed for 15 minutes. The levels of antibodies to MCPS ant to OMV present in the controls and samples were obtained from a standard curve using the reference standard which has an assigned value of 100 ELISA units/ml. The results are shown in Table 2 and Figures 1A and 1B.

The results summarized in Table 2 and Figures 1A and 1B reveal that the combination vaccine was immunogenic, as measured by NmB and NmC IgG antibody titers, respectively. Figure 1A shows that a specific anti-meningococcal B antibody response was induced by the vaccine combinations comprising NmB. Figure 1B shows that a specific anti-meningococcal C antibody response was induced by the vaccine combinations comprising NmC. In particular, the antibody response induced by the combination of the NmC conjugate and NmB in the presence of MF59 adjuvant (Group 5) was significantly greater than the antibody response induced by either the NmC conjugate alone (Group 1) or the combination of the NmC conjugate and NmB in the presence of alum (Group 4). When the adjuvant MF59 was present, the antibody titer for the combination vaccine increased approximately six-fold.

**Table 2: IgG MenC Antibody Responses (GMT)**

Vaccine	Adjuvant	SCN Assay	
		Post-1	Post-2
MenC Conj.	Alum	20.3	155
MenB	Alum	<1	<1
MenC Ps + MenB	Alum	<1	1.5

MenC Conj. + MenB	Alum	9.5	71
MenC Conj. + MenB	MF59	15.2	426
none	Alum	<1	<1

5

**Example 2: Bactericidal Titers**

Serum samples were tested for complement-mediated bactericidal titers to MenC strain 60E and MenB strain 44/76. Bactericidal titers were assayed on pooled sera from each group. Bactericidal data were generated using human complement.

10

Components of the assay (i.e., buffer, antibody, complement, and bacteria) were added to sterile, 96-well tissue culture plates with lids (Nunc # 167008). The plates were maintained at room temperature during the assay. To each well, 50  $\mu$ l Gey's buffer (Gibco) containing 1% RIA Grade BSA (Sigma), 25  $\mu$ l of the diluted test antibody, 25  $\mu$ l of bacteria diluted 1:8000 in Gey's buffer/1% BSA, were sequentially added. Control wells include 1) Gey's buffer/1% BSA and bacteria alone (to determine if the organisms are viable in the diluent alone); 2) a time 0 control containing 75  $\mu$ l buffer, 25  $\mu$ l heat-inactivated (56°C, 30 min.) human complement, and 25  $\mu$ l bacteria; and 3) a toxicity control testing the complement at 20% and 40% with buffer and bacteria to verify that the complement source is non-toxic to the test strain. All antibody samples (at the highest concentration assayed) were also tested with heat-inactivated complement to show that a decrease in colony forming units (cfu) in the presence of antibody is complement dependent. After all reagents were added, 22  $\mu$ l was taken from each control well and plated onto Mueller-Hinton agar plates by allowing the sample to run from the top to the bottom of the plate, to determine the cfu in the well at 0 min. The microtiter plates were then covered and sealed with parafilm, and rotated gently for 1 hour at 37°C in a 4% CO<sub>2</sub> incubator. The plates were then removed, and a 22  $\mu$ l sample from each well plated on Mueller-Hinton agar. The culture plates were incubated for about 18 hours at 37°C, with 4% CO<sub>2</sub>. The colonies were counted, and % survival determined for each test well: % survival = ([cfu of sample well at 60 min]/[cfu in the heat inactivated complement control well at time 0 min.]) x 100. Bactericidal titers reported are those which resulted in 50% survival. Results from a single experiment are presented in Table 3. Results are also

30

presented in Figures 2A and 2B, with Figure 2B representing average titers from a plurality of experiments.

As the results summarized in Table 3 reveal, the combination vaccine elicited high titers of serum bactericidal antibody for both NmB and NmC. Bactericidal NmC antibody titer was slightly higher for the combination vaccine using MF59 as the carrier, but there was essentially no effect on bactericidal NmB titer using MF59. Interestingly, two- to five-fold higher NmB bactericidal titers were obtained with the combination vaccine than with the NmB vaccine alone. Figure 2A demonstrates that the antibodies directed to meningococcal B induced by the vaccine combinations comprising NmB were bactericidal. Figure 2B demonstrates that the antibodies directed to meningococcal C induced by the vaccine combinations comprising NmC conjugate were also bactericidal.

**Table 3**

Group Vaccine	NmC (1/titer)			NmB (1/titer)		
	Pre	Post-1	Post-2	Pre	Post-1	Post-2
NmC conj. + Alum	<5	80	>3375	<5	<5	<5
NmB + Alum	<5	<5	15	<5	15	800
NmC Ps + NmB + Alum	<5	<5	30	<5	25	1500
NmC Conj. + NmB + Alum	<5	25	2000	<5	25	5000
NmC Conj. + NmB + MF59	<5	50	>3375	<5	25	4000
Alum	<5	<5	<5	<5	<5	<5

### Example 3: Comparison of Alum and MF59 Adjuvants

Serum from the animals described above in Figures 1A and 1B were compared and MenC and MenB antibody responses generated by NmB/NmC conj. in either alum or MF59 adjuvant were detected as described above in Examples 1 and 2. The results, shown in Figure 3, demonstrate that the antibody response to meningococcal C was approximately

- 10 -

6-fold greater in vaccines comprising MF59 adjuvant.

**Example 4: Comparison of Antibody Responses Generated by Combination Vaccine to Monovalent Vaccines**

5                   Serum from the animals described above in Figures 1A and 1B were compared and MenC and MenB antibody responses generated by NmB/NmC conj. were compared with the antibody responses generated by either the NmB vaccine alone or the NmC conj. alone in alum as described above in Examples 1 and 2. The results, shown in Figure 4, demonstrate that there is no significant difference in the antibody responses to the components of the  
10 NmB/NmC conj. vaccine compared to the responses induced by the respective monovalent vaccines (either NmB or NmC conj.).



- 11 -

**WHAT IS CLAIMED IS:**

1. An immunogenic composition comprising NmC oligosaccharide conjugated to a first carrier and NmB outer membrane protein.
2. The immunogenic composition of claim 1 wherein said first carrier is selected from the group consisting of protein, polysaccharide, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid co-polymer, lipid aggregate, and inactive virus particle.
3. The immunogenic composition of claim 2 wherein said first carrier is a protein.
4. The immunogenic composition of claim 3 wherein said first carrier is CRM<sub>197</sub>.
5. The immunogenic composition of claim 1 the NmB outer membrane protein is presented as proteoliposomic vesicles.
6. The immunogenic composition of claim 1 wherein said composition comprises a second carrier.
7. The immunogenic composition of claim 6 wherein said second carrier is aluminum hydroxide or MF59.
8. A method of inducing an immunologic response to NmB and NmC comprising administering an immunologically effective amount of an immunogenic composition of claim 1.
9. The method of claim 8 wherein said first carrier is selected from the group consisting of protein, polysaccharide, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid co-polymer, lipid aggregate, and inactive virus particle.
10. The method of claim 9 wherein said first carrier is a protein.

- 12 -

11. The method of claim 10 wherein said first carrier is CRM<sub>197</sub>.
12. The method of claim 8 the NmB outer membrane protein is presented as proteoliposomic vesicles.
- 5 13. The method of claim 8 wherein said composition comprises a second carrier.
14. The method of claim 13 wherein said second carrier is aluminum hydroxide or MF59.
- 10 15. A vaccine comprising an immunogenic composition of any one of claims 1-7.
16. A method of vaccinating an individual comprising administering to said individual an immunogenic composition of any one of claims 1-7.

1/4

Figure 1A





Figure 1B





2/4  
Figure 2A

Figure 2B



**Figure 3**

<b>Ratios of Antibody Responses of Animals given Combination MenB OMV / MenC Conjugate with MF59 or Al(OH)<sub>3</sub></b>			
<b>Assay</b>		<b>Ratio of GMT MF59 : GMT Al(OH)<sub>3</sub></b>	
		<b>28 days Post - 1</b>	<b>18 days Post - 2</b>
<b>MenC</b>	<b>IgG</b>	<b>1.6</b>	<b>6.0**</b>
	<b>Bactericidal</b>	<b>1.0*</b>	<b>1.2*</b>
<b>MenB</b>	<b>IgG</b>	<b>0.7</b>	<b>1.4</b>
	<b>Bactericidal</b>	<b>0.9</b>	<b>1.4</b>
*Pooled sera only tested		**P ≤ 0.001	

Figure 4

Ratios of Antibody Responses of Animals given Combination / Al(OH) <sub>3</sub> vs. Monovalent / Al(OH) <sub>3</sub>			
Assay		Ratio of GMT Combo : GMT Mono	
		28 days Post - 1	18 days Post - 2
MenC	IgG	0.5	0.5
	Bactericidal	0.2*	0.7*
MenB	IgG	1.3	1.2
	Bactericidal	1.6	2.9**
*Pooled sera only tested.			
**P ≤ 0.05			

PCT

09/701,453

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>01528.001</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 11977</b>	International filing date (day/month/year) <b>28/05/1999</b>	(Earliest) Priority Date (day/month/year) <b>29/05/1998</b>
Applicant  <b>CHIRON CORPORATION et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 11977

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-14 16  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K39/095 A61K39/39 A61K9/127 A61K39/385

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 90 06696 A (RIJKINSINSTITUUT VOOR VOLKSGEZ ; PRAXIS BIOLOG INC (US)) 28 June 1990 (1990-06-28) page 4, line 6-20 page 9, line 1 - page 10, line 7 examples 2,7,10,15 claims --- -/--	1-16

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

6 August 1999

Date of mailing of the international search report

24/08/1999

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Covone, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LIEBERMAN J M ET AL: "Safety and immunogenicity of a serogroups A/C <i>Neisseria meningitidis</i> oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial." JAMA, (1996 MAY 15) 275 (19) 1499-503. , XP002111434  page 1500, column 2, paragraph 2  page 1503, column 1, paragraph 3 - column 2  see reference 33  tables 2,3  figure 2</p>	1-4, 6-11, 13-16
A	<p>MILAGRES L G ET AL: "Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine." FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, (1996 JAN) 13 (1) 9-17. , XP002111435  abstract  page 9, left-hand column, paragraph 1  page 10, left-hand column, paragraph 5  page 15, right-hand column, paragraph 2 -  page 16, right-hand column  figure 5</p>	1-19
A	<p>DEBBAG R ET AL.: "Evaluation of adverse reactions associated to antimeningococcal BC vaccination in 16.700 children" CLIN.INFECT.DIS., vol. 21, September 1995 (1995-09), page 790-A420 XP002111436  the whole document</p>	1-19
A	<p>GRANOFF D M ET AL: "MF59 adjuvant enhances antibody responses of infant baboons immunized with <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> group C oligosaccharide - CRM197 conjugate vaccine." INFECTION AND IMMUNITY, (1997 MAY) 65 (5) 1710-5. , XP002081016  abstract  table 1  page 1711, left-hand column, paragraphs 3,4  page 1713, right-hand column, paragraph 2  - page 1714, left-hand column, paragraph 1  page 1714, right-hand column, paragraph 2</p>	1-19

-/--

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	ROSENQVIST E ET AL: "Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine." DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, (1998) 92 323-33. , XP002111437 abstract tables 1,2 page 324, paragraph 2 page 329, paragraph 2 page 332, paragraph 2 ----	1-19
T	DATABASE MEDLINE 'Online! US national library of medicine (nlm) Bethesda , MD, US DIAZ ROMERO J ET AL.: "Current status of meningococcal group B vaccine candidates: capsular or noncapsular?" retrieved from STN Database accession no. 95136208 XP002111438 abstract & CLINICAL MICROBIOLOGY REVIEWS, vol. 7, no. 4, October 1994 (1994-10), pages 559-75, -----	1-16

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9006696 A	28-06-1990	NL 8803111 A	16-07-1990
		NL 8900030 A	01-08-1990
		NL 8901612 A	16-07-1990
		AT 120093 T	15-04-1995
		AU 640118 B	19-08-1993
		AU 4821990 A	10-07-1990
		DE 68921895 D	27-04-1995
		DE 68921895 T	07-09-1995
		DK 117491 A	15-08-1991
		EP 0449958 A	09-10-1991
		ES 2070312 T	01-06-1995
		JP 6503465 T	21-04-1994
		NL 8900036 A	16-07-1990
		NO 305463 B	07-06-1999
		CA 2000735 A	06-07-1990
		CA 2007248 A	06-07-1990
		DE 8901378 U	23-03-1989
		DK 511389 A	07-07-1990
		EP 0377233 A	11-07-1990
		US 5057007 A	15-10-1991
		PT 92807 A,B	31-07-1990

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 8-14,16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Claims Nos.: 8-14 16

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy